Gestational and Pathological Regulation of Placental Drug Transporters: Implications for Maternal–Fetal Drug Exposure and Developmental Safety

Whilst the placenta provides a partially selective barrier to drug transfer between maternal and fetal circulations, many drugs can still be transferred to the fetus to some degree. Whether a drug reaches the fetus will depend on drug properties, passive diffusion and active transport processes via placental transporters. This review provides an overview of how placental transporters are regulated throughout gestation and by pathology. This will impact on drug exposure in the mother and fetus. There are a number of transporter superfamilies including ATP-binding cassette transporters (ABC). The ABC transporters that have been identified within the placenta include P-glycoprotein (P-gp/ABCB1), breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance associated proteins (MRPs). Transporters from the solute carrier family (SLC) have also been identified including organic anion transporters, organic anion transporting polypeptides and organic cation transporters. Some drugs may not reach the fetus due to P-gp and BCRP acting as barriers to transfer by transporting selected substrates back into the maternal circulation. On the other hand SLC transporters play a role in drug uptake and exchange. There may be changes in transporter expression throughout gestation. Infection, inflammation, metabolic disturbances and other complications can affect placental transporter regulation. Molecular factors have been shown to play a role including inflammation via cytokines, oxidative stress, hypoxia, hormone signalling and nuclear receptors. Genetic polymorphism and epigenetic mechanisms can also affect transporter expression. This may alter drug exposure to the fetus. However, it cannot be determined from placental transporter expression if a drug will transfer or if a drug will result in toxicity. Experimental models have been developed to investigate placental transporters including trophoblast models, ex-vivo placental perfusion, placental organoids, physiologically based pharmacokinetic modelling, and multi-omics. To improve prediction of fetal drug exposure, more functional data is required for specific gestations and diseases and also integrating clinical pharmacokinetics.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24415431
Primary Topic
Drug Transport and Resistance Mechanisms
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Gestational and Pathological Regulation of Placental Drug Transporters: Implications for Maternal–Fetal Drug Exposure and Developmental Safety

Upadesh Lade, Kunal Zode, Priyanka Lilhare, Revati Donode et al.
Zenodo (CERN European Organization for Nuclear Research)
Drug Transport and Resistance Mechanisms
article

Gestational and Pathological Regulation of Placental Drug Transporters: Implications for Maternal–Fetal Drug Exposure and Developmental Safety

Upadesh Lade, Kunal Zode, Priyanka Lilhare, Revati Donode, Yogini Kawale
article en

Abstract

Whilst the placenta provides a partially selective barrier to drug transfer between maternal and fetal circulations, many drugs can still be transferred to the fetus to some degree. Whether a drug reaches the fetus will depend on drug properties, passive diffusion and active transport processes via placental transporters. This review provides an overview of how placental transporters are regulated throughout gestation and by pathology. This will impact on drug exposure in the mother and fetus. There are a number of transporter superfamilies including ATP-binding cassette transporters (ABC). The ABC transporters that have been identified within the placenta include P-glycoprotein (P-gp/ABCB1), breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance associated proteins (MRPs). Transporters from the solute carrier family (SLC) have also been identified including organic anion transporters, organic anion transporting polypeptides and organic cation transporters. Some drugs may not reach the fetus due to P-gp and BCRP acting as barriers to transfer by transporting selected substrates back into the maternal circulation. On the other hand SLC transporters play a role in drug uptake and exchange. There may be changes in transporter expression throughout gestation. Infection, inflammation, metabolic disturbances and other complications can affect placental transporter regulation. Molecular factors have been shown to play a role including inflammation via cytokines, oxidative stress, hypoxia, hormone signalling and nuclear receptors. Genetic polymorphism and epigenetic mechanisms can also affect transporter expression. This may alter drug exposure to the fetus. However, it cannot be determined from placental transporter expression if a drug will transfer or if a drug will result in toxicity. Experimental models have been developed to investigate placental transporters including trophoblast models, ex-vivo placental perfusion, placental organoids, physiologically based pharmacokinetic modelling, and multi-omics. To improve prediction of fetal drug exposure, more functional data is required for specific gestations and diseases and also integrating clinical pharmacokinetics.

Zenodo (CERN European Organization for Nuclear Research)
Drug Transport and Resistance Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon